Yu and colleagues suggested that STAT3 upregulated the expression of various target genes (Bcl-2, cyclin D1, c-myc) through a miR-197/CKS1B/STAT3 axis, which conferred chemoresistance to non-small-cell lung cancer [101]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.